Oxford Ion Sight is a technology spin-out unlocking the potential of native mass spectrometry to transform drug discovery. Our AI-driven analytical platform enables scalable, high-throughput insights into protein structure and interactions under near-physiological conditions – capabilities previously considered out of reach at scale. Our mission is to deliver actionable structural biology and biophysics at speed, empowering drug developers with the clarity needed to accelerate pipeline decisions and reduce attrition.
Founders
Oxford Ion Sight was founded by a team of experts from the University of Oxford with extensive experience in native mass spectrometry, technology development, and machine learning.
Dr Rod Chalk
CEO
Dr Weston Struwe
CSO
Dr Mark van der Wilk
CTO
Get in touch
To get in touch with the team, email us at contact@ionsight.bio